Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 24;13:6321. doi: 10.1038/s41467-022-34036-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Flow cytometry assay of dendritic cell maturation in the lymph nodes after treatments with PBS, aPD-1, VNP@Gel, GD/EI-NP@Gel, VNP-GD@Gel, VNP-GD/EI-NP@Gel and VNP-GD/EI-NP@Gel+aPD-1 (n = 4 mice). b Flow cytometry assay of CD8⁺ T cell infiltration in the tumor tissue after treatments as mentioned above, n = 4 mice. c Dendritic cell maturation in the lymph nodes after different treatments. Data are shown as mean ± s.d. and analyzed with one way ANOVA followed by Tukey’s multiple comparisons test, n = 4 mice (VNP-GD@Gel vs. VNP-GD/EI-NP@Gel: ***P = 0.0008; VNP-GD@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: ***P = 0.0002; VNP-GD/EI-NP@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: ^nsP = 0.4116). d The number of CD8⁺ T cells per mg tumor tissue after different treatments. Data are shown as mean ± s.d. and analyzed with one way ANOVA followed by Tukey’s multiple comparisons test, n = 4 mice (VNP-GD@Gel vs. VNP-GD/EI-NP@Gel: *P = 0.0215; VNP-GD@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: ****P < 0.0001; VNP-GD/EI-NP@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: **P = 0.0042). e The number of Granzyme B⁺CD8⁺ T cells per mg tumor tissue after different treatments, n = 4 mice (VNP-GD@Gel vs. VNP-GD/EI-NP@Gel: **P = 0.0065 VNP-GD@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: ****P < 0.0001; VNP-GD/EI-NP@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: **P = 0.0028). HMGB1 (f), IFNγ (g), and TNFα (h) expressions in the tumor tissues after different treatments detected by ELISA. Data are shown as mean ± s.d. and analyzed with one way ANOVA followed by Tukey’s multiple comparisons test, n = 4 mice. (f, VNP-GD@Gel vs. VNP-GD/EI-NP@Gel: **P = 0.0080; VNP-GD@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: **P = 0.0017; VNP-GD/EI-NP@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: ^nsP = 0.5319. g, VNP-GD@Gel vs. VNP-GD/EI-NP@Gel: *P = 0.0256; VNP-GD@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: ***P = 0.0002; VNP-GD/EI-NP@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: *P = 0.0127. h, VNP-GD@Gel vs. VNP-GD/EI-NP@Gel: **P = 0.0047; VNP-GD@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: ****P < 0.0001; VNP-GD/EI-NP@Gel vs. VNP-GD/EI-NP@Gel+aPD-1: **P = 0.0053.) i Luminex-based quantification of cytokines and chemokines, including IL-1α, IFN-γ, TNF-α, MCP-1, IL-12, IL-1β, IL-6, IL-27, IL-17A, GM-CSF (n = 5 mice). Source data are provided as a Source Data file.